| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 111 | 2025 | 1080 | 15.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 136 | 2025 | 2600 | 12.920 |
Why?
|
| Lung Neoplasms | 162 | 2024 | 2409 | 12.880 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 114 | 2024 | 1149 | 12.450 |
Why?
|
| Carcinoma, Squamous Cell | 78 | 2025 | 1089 | 8.100 |
Why?
|
| Chemoradiotherapy | 35 | 2025 | 331 | 5.160 |
Why?
|
| Antineoplastic Agents | 76 | 2024 | 2348 | 4.600 |
Why?
|
| Neoplasm Recurrence, Local | 56 | 2025 | 1504 | 4.590 |
Why?
|
| Small Cell Lung Carcinoma | 25 | 2024 | 136 | 4.130 |
Why?
|
| Papillomavirus Infections | 16 | 2025 | 308 | 3.780 |
Why?
|
| Oropharyngeal Neoplasms | 11 | 2025 | 151 | 3.660 |
Why?
|
| Carboplatin | 45 | 2025 | 329 | 3.390 |
Why?
|
| Paclitaxel | 43 | 2025 | 482 | 2.920 |
Why?
|
| Combined Modality Therapy | 65 | 2024 | 1738 | 2.820 |
Why?
|
| Quinazolines | 23 | 2023 | 220 | 2.730 |
Why?
|
| ErbB Receptors | 34 | 2025 | 515 | 2.570 |
Why?
|
| Aged | 195 | 2025 | 21309 | 2.450 |
Why?
|
| Humans | 362 | 2025 | 96382 | 2.440 |
Why?
|
| Protein Kinase Inhibitors | 22 | 2022 | 631 | 2.420 |
Why?
|
| Neoplasm Staging | 80 | 2024 | 2055 | 2.410 |
Why?
|
| Disease-Free Survival | 59 | 2024 | 1184 | 2.370 |
Why?
|
| Middle Aged | 199 | 2025 | 28794 | 2.190 |
Why?
|
| Adenocarcinoma | 26 | 2023 | 1198 | 2.190 |
Why?
|
| Male | 219 | 2025 | 46116 | 1.970 |
Why?
|
| Cetuximab | 15 | 2020 | 119 | 1.950 |
Why?
|
| Neoadjuvant Therapy | 11 | 2025 | 467 | 1.940 |
Why?
|
| Survival Rate | 56 | 2024 | 2019 | 1.920 |
Why?
|
| Aged, 80 and over | 102 | 2024 | 7277 | 1.890 |
Why?
|
| Female | 223 | 2025 | 50528 | 1.880 |
Why?
|
| Adult | 162 | 2025 | 28968 | 1.800 |
Why?
|
| Papillomaviridae | 11 | 2025 | 183 | 1.770 |
Why?
|
| Treatment Outcome | 92 | 2025 | 9526 | 1.700 |
Why?
|
| Antibodies, Monoclonal | 23 | 2024 | 1408 | 1.690 |
Why?
|
| Indoles | 18 | 2023 | 332 | 1.650 |
Why?
|
| Antineoplastic Agents, Immunological | 8 | 2022 | 229 | 1.650 |
Why?
|
| Survival Analysis | 45 | 2020 | 1525 | 1.530 |
Why?
|
| Clinical Trials as Topic | 24 | 2021 | 1118 | 1.500 |
Why?
|
| Cisplatin | 31 | 2022 | 575 | 1.490 |
Why?
|
| Induction Chemotherapy | 12 | 2022 | 147 | 1.480 |
Why?
|
| Carcinoma, Small Cell | 11 | 2017 | 116 | 1.480 |
Why?
|
| Taxoids | 17 | 2017 | 126 | 1.450 |
Why?
|
| Antibodies, Monoclonal, Humanized | 21 | 2025 | 1065 | 1.450 |
Why?
|
| Fluorouracil | 26 | 2022 | 534 | 1.430 |
Why?
|
| Radiotherapy Dosage | 31 | 2023 | 478 | 1.420 |
Why?
|
| Camptothecin | 14 | 2013 | 197 | 1.390 |
Why?
|
| Pyrroles | 7 | 2017 | 165 | 1.290 |
Why?
|
| Hydroxyurea | 21 | 2022 | 232 | 1.270 |
Why?
|
| Radiotherapy | 15 | 2011 | 322 | 1.270 |
Why?
|
| Biomarkers, Tumor | 22 | 2025 | 1722 | 1.250 |
Why?
|
| Carcinoma | 9 | 2022 | 440 | 1.240 |
Why?
|
| Radiation-Sensitizing Agents | 6 | 2013 | 97 | 1.200 |
Why?
|
| Neoplasms | 20 | 2025 | 3271 | 1.160 |
Why?
|
| Precision Medicine | 8 | 2025 | 484 | 1.130 |
Why?
|
| Circulating Tumor DNA | 3 | 2025 | 80 | 1.120 |
Why?
|
| DNA, Viral | 4 | 2025 | 237 | 1.100 |
Why?
|
| Nasopharyngeal Neoplasms | 4 | 2023 | 48 | 1.080 |
Why?
|
| Laryngeal Neoplasms | 5 | 2013 | 89 | 1.070 |
Why?
|
| Medical Oncology | 8 | 2023 | 413 | 1.050 |
Why?
|
| Prognosis | 48 | 2024 | 4041 | 1.040 |
Why?
|
| Benzimidazoles | 4 | 2021 | 116 | 1.030 |
Why?
|
| Mouth Neoplasms | 9 | 2018 | 209 | 1.020 |
Why?
|
| Deoxycytidine | 14 | 2012 | 216 | 1.020 |
Why?
|
| Proto-Oncogene Proteins c-met | 16 | 2021 | 199 | 1.010 |
Why?
|
| Drug Resistance, Neoplasm | 13 | 2021 | 653 | 0.980 |
Why?
|
| Chemotherapy, Adjuvant | 20 | 2015 | 522 | 0.980 |
Why?
|
| Sirolimus | 3 | 2020 | 180 | 0.970 |
Why?
|
| Etoposide | 16 | 2024 | 207 | 0.960 |
Why?
|
| Clinical Trials, Phase III as Topic | 11 | 2025 | 165 | 0.950 |
Why?
|
| Maximum Tolerated Dose | 14 | 2022 | 263 | 0.940 |
Why?
|
| Mesothelioma | 13 | 2017 | 337 | 0.920 |
Why?
|
| Randomized Controlled Trials as Topic | 14 | 2025 | 975 | 0.920 |
Why?
|
| Vascular Endothelial Growth Factor A | 11 | 2023 | 397 | 0.900 |
Why?
|
| Immunotherapy | 9 | 2025 | 800 | 0.900 |
Why?
|
| Pneumonectomy | 5 | 2024 | 219 | 0.890 |
Why?
|
| Neoplasm Metastasis | 21 | 2025 | 1079 | 0.880 |
Why?
|
| Antibodies, Bispecific | 1 | 2025 | 45 | 0.860 |
Why?
|
| Salvage Therapy | 9 | 2014 | 235 | 0.830 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 3 | 2021 | 86 | 0.820 |
Why?
|
| Quality of Life | 17 | 2024 | 1869 | 0.810 |
Why?
|
| Guanine | 8 | 2014 | 194 | 0.800 |
Why?
|
| Clinical Trials, Phase II as Topic | 9 | 2024 | 162 | 0.790 |
Why?
|
| Esophageal Neoplasms | 5 | 2012 | 350 | 0.790 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2023 | 62 | 0.750 |
Why?
|
| Biomarkers | 6 | 2022 | 1977 | 0.740 |
Why?
|
| Neoplasms, Second Primary | 8 | 2011 | 244 | 0.740 |
Why?
|
| Angiogenesis Inhibitors | 9 | 2016 | 279 | 0.740 |
Why?
|
| Re-Irradiation | 1 | 2022 | 17 | 0.730 |
Why?
|
| Deglutition | 9 | 2020 | 85 | 0.710 |
Why?
|
| Disease Progression | 23 | 2023 | 1586 | 0.700 |
Why?
|
| Human papillomavirus 16 | 3 | 2025 | 45 | 0.700 |
Why?
|
| Kaplan-Meier Estimate | 17 | 2017 | 899 | 0.690 |
Why?
|
| Radiotherapy, Conformal | 5 | 2011 | 87 | 0.690 |
Why?
|
| Pancreatic Neoplasms | 4 | 2010 | 750 | 0.680 |
Why?
|
| Liver Neoplasms | 8 | 2018 | 813 | 0.670 |
Why?
|
| Drug Monitoring | 2 | 2022 | 165 | 0.650 |
Why?
|
| Bevacizumab | 11 | 2017 | 255 | 0.650 |
Why?
|
| B7-H1 Antigen | 8 | 2025 | 320 | 0.640 |
Why?
|
| Cyclooxygenase 2 | 4 | 2017 | 102 | 0.630 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 110 | 0.630 |
Why?
|
| Carcinoma, Large Cell | 7 | 2014 | 37 | 0.620 |
Why?
|
| Enzyme Inhibitors | 7 | 2014 | 639 | 0.610 |
Why?
|
| Tumor Microenvironment | 4 | 2025 | 600 | 0.600 |
Why?
|
| Pemetrexed | 10 | 2020 | 76 | 0.600 |
Why?
|
| Thyroid Neoplasms | 2 | 2023 | 462 | 0.600 |
Why?
|
| Thoracic Neoplasms | 4 | 2018 | 64 | 0.590 |
Why?
|
| Glutamates | 6 | 2014 | 84 | 0.550 |
Why?
|
| Drug Administration Schedule | 17 | 2020 | 836 | 0.550 |
Why?
|
| Vinblastine | 3 | 2002 | 84 | 0.540 |
Why?
|
| Terminal Care | 1 | 2019 | 147 | 0.540 |
Why?
|
| Organoplatinum Compounds | 4 | 2006 | 95 | 0.520 |
Why?
|
| Time Factors | 21 | 2021 | 5524 | 0.520 |
Why?
|
| Follow-Up Studies | 24 | 2021 | 3969 | 0.520 |
Why?
|
| Erlotinib Hydrochloride | 11 | 2022 | 86 | 0.510 |
Why?
|
| Quality of Health Care | 2 | 2019 | 386 | 0.500 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2014 | 400 | 0.500 |
Why?
|
| Stomach Neoplasms | 3 | 2011 | 308 | 0.490 |
Why?
|
| Radiosurgery | 4 | 2024 | 343 | 0.490 |
Why?
|
| Thionucleotides | 2 | 2008 | 54 | 0.470 |
Why?
|
| Pleural Neoplasms | 6 | 2024 | 203 | 0.470 |
Why?
|
| Salivary Gland Neoplasms | 5 | 2025 | 84 | 0.470 |
Why?
|
| Cell Line, Tumor | 23 | 2025 | 2839 | 0.460 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 3 | 2011 | 18 | 0.460 |
Why?
|
| Organ Sparing Treatments | 2 | 2013 | 52 | 0.460 |
Why?
|
| Neoplasms, Squamous Cell | 2 | 2015 | 19 | 0.460 |
Why?
|
| Colorectal Neoplasms | 5 | 2011 | 1087 | 0.450 |
Why?
|
| Radiotherapy, Adjuvant | 12 | 2015 | 317 | 0.450 |
Why?
|
| Patient Selection | 8 | 2021 | 714 | 0.440 |
Why?
|
| Speech | 2 | 2013 | 90 | 0.440 |
Why?
|
| Remission Induction | 10 | 2014 | 741 | 0.430 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2025 | 554 | 0.430 |
Why?
|
| Exanthema | 3 | 2014 | 42 | 0.420 |
Why?
|
| Neoplasm Invasiveness | 7 | 2024 | 577 | 0.420 |
Why?
|
| Pyridines | 5 | 2019 | 314 | 0.410 |
Why?
|
| Platinum Compounds | 3 | 2022 | 29 | 0.410 |
Why?
|
| Lymph Nodes | 6 | 2023 | 559 | 0.400 |
Why?
|
| Neck Dissection | 6 | 2010 | 67 | 0.390 |
Why?
|
| Blood Proteins | 1 | 2014 | 146 | 0.390 |
Why?
|
| Retrospective Studies | 27 | 2023 | 10719 | 0.390 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 5 | 2015 | 158 | 0.380 |
Why?
|
| Neutropenia | 6 | 2017 | 211 | 0.380 |
Why?
|
| DNA Repair | 2 | 2014 | 362 | 0.380 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2025 | 1372 | 0.370 |
Why?
|
| DNA-Binding Proteins | 3 | 2015 | 1248 | 0.370 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 4 | 2023 | 58 | 0.360 |
Why?
|
| Protein-Tyrosine Kinases | 6 | 2017 | 304 | 0.360 |
Why?
|
| Radiotherapy, Intensity-Modulated | 5 | 2016 | 194 | 0.360 |
Why?
|
| Mutation | 18 | 2023 | 4325 | 0.360 |
Why?
|
| Platinum | 7 | 2022 | 67 | 0.360 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2013 | 245 | 0.360 |
Why?
|
| Molecular Targeted Therapy | 3 | 2020 | 316 | 0.360 |
Why?
|
| Publishing | 1 | 2013 | 92 | 0.350 |
Why?
|
| Sulfonamides | 9 | 2014 | 344 | 0.350 |
Why?
|
| Proteomics | 1 | 2014 | 269 | 0.350 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 3 | 2017 | 37 | 0.330 |
Why?
|
| Prospective Studies | 15 | 2025 | 4742 | 0.330 |
Why?
|
| Signal Transduction | 11 | 2019 | 3563 | 0.330 |
Why?
|
| Antineoplastic Agents, Phytogenic | 5 | 2012 | 271 | 0.330 |
Why?
|
| Carcinoma, Adenoid Cystic | 3 | 2025 | 45 | 0.330 |
Why?
|
| Receptors, Growth Factor | 5 | 2011 | 52 | 0.330 |
Why?
|
| Proportional Hazards Models | 9 | 2019 | 906 | 0.330 |
Why?
|
| Area Under Curve | 6 | 2018 | 339 | 0.320 |
Why?
|
| Alphapapillomavirus | 2 | 2021 | 46 | 0.320 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 528 | 0.320 |
Why?
|
| Multicenter Studies as Topic | 3 | 2025 | 194 | 0.320 |
Why?
|
| Lung | 3 | 2013 | 1389 | 0.310 |
Why?
|
| Methotrexate | 2 | 2017 | 226 | 0.310 |
Why?
|
| Receptor, EphB4 | 3 | 2015 | 23 | 0.300 |
Why?
|
| Age Factors | 7 | 2018 | 1957 | 0.300 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2018 | 1937 | 0.300 |
Why?
|
| Maintenance Chemotherapy | 3 | 2020 | 94 | 0.300 |
Why?
|
| Administration, Oral | 9 | 2020 | 665 | 0.290 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2017 | 676 | 0.290 |
Why?
|
| Piperazines | 8 | 2019 | 303 | 0.290 |
Why?
|
| Carmustine | 2 | 2006 | 70 | 0.290 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 2 | 2006 | 117 | 0.290 |
Why?
|
| Immunologic Factors | 3 | 2023 | 178 | 0.280 |
Why?
|
| Oxides | 1 | 2008 | 42 | 0.280 |
Why?
|
| Cohort Studies | 10 | 2021 | 3157 | 0.280 |
Why?
|
| Immunoconjugates | 2 | 2021 | 136 | 0.280 |
Why?
|
| Arsenicals | 1 | 2008 | 49 | 0.280 |
Why?
|
| Immunohistochemistry | 10 | 2020 | 1805 | 0.280 |
Why?
|
| Fatigue | 3 | 2018 | 185 | 0.270 |
Why?
|
| Infusions, Intravenous | 8 | 2018 | 411 | 0.270 |
Why?
|
| Smoking | 6 | 2014 | 669 | 0.270 |
Why?
|
| Pharmacogenetics | 3 | 2025 | 468 | 0.270 |
Why?
|
| International Cooperation | 3 | 2018 | 132 | 0.260 |
Why?
|
| Peritoneal Neoplasms | 4 | 2012 | 194 | 0.260 |
Why?
|
| Indazoles | 4 | 2013 | 62 | 0.260 |
Why?
|
| Prostatic Neoplasms | 5 | 2011 | 1793 | 0.260 |
Why?
|
| Pyrimidines | 4 | 2012 | 408 | 0.250 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2025 | 551 | 0.250 |
Why?
|
| Human papillomavirus 18 | 2 | 2025 | 22 | 0.250 |
Why?
|
| Suramin | 2 | 2004 | 25 | 0.250 |
Why?
|
| DNA | 1 | 2012 | 1270 | 0.250 |
Why?
|
| Alkyl and Aryl Transferases | 2 | 2003 | 17 | 0.250 |
Why?
|
| Multivariate Analysis | 8 | 2019 | 1007 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 3 | 2016 | 1090 | 0.240 |
Why?
|
| Phosphorylcholine | 1 | 2006 | 22 | 0.240 |
Why?
|
| Niacinamide | 5 | 2013 | 104 | 0.240 |
Why?
|
| Thiazoles | 3 | 2012 | 126 | 0.240 |
Why?
|
| Deglutition Disorders | 4 | 2011 | 124 | 0.240 |
Why?
|
| Young Adult | 10 | 2022 | 7318 | 0.240 |
Why?
|
| Benzenesulfonates | 3 | 2010 | 49 | 0.240 |
Why?
|
| Risk Factors | 12 | 2018 | 6120 | 0.240 |
Why?
|
| Double-Blind Method | 5 | 2017 | 1759 | 0.230 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2021 | 107 | 0.230 |
Why?
|
| Tubulin Modulators | 2 | 2021 | 23 | 0.230 |
Why?
|
| Gallbladder Neoplasms | 1 | 2005 | 24 | 0.230 |
Why?
|
| Anemia | 4 | 2017 | 130 | 0.230 |
Why?
|
| Cell Plasticity | 1 | 2025 | 24 | 0.230 |
Why?
|
| Neovascularization, Pathologic | 2 | 2008 | 355 | 0.230 |
Why?
|
| Dacarbazine | 1 | 2006 | 103 | 0.230 |
Why?
|
| Mouth | 2 | 2018 | 47 | 0.230 |
Why?
|
| Amphiregulin | 1 | 2025 | 16 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2010 | 206 | 0.220 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2005 | 136 | 0.220 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2025 | 22 | 0.220 |
Why?
|
| Imidazoles | 4 | 2013 | 142 | 0.220 |
Why?
|
| Confidence Intervals | 5 | 2018 | 219 | 0.210 |
Why?
|
| Patient Portals | 1 | 2025 | 35 | 0.210 |
Why?
|
| Bile Duct Neoplasms | 1 | 2005 | 95 | 0.210 |
Why?
|
| Mice | 15 | 2025 | 12495 | 0.210 |
Why?
|
| Herpesvirus 4, Human | 2 | 2023 | 122 | 0.210 |
Why?
|
| Boronic Acids | 3 | 2011 | 56 | 0.210 |
Why?
|
| Cyclosporine | 1 | 2005 | 241 | 0.210 |
Why?
|
| Oligopeptides | 1 | 2005 | 205 | 0.210 |
Why?
|
| Radiography | 4 | 2014 | 756 | 0.210 |
Why?
|
| Radiation Dosage | 3 | 2020 | 231 | 0.210 |
Why?
|
| Sarcoma | 1 | 2006 | 220 | 0.210 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2024 | 30 | 0.210 |
Why?
|
| Neutrophils | 1 | 2025 | 337 | 0.200 |
Why?
|
| Feasibility Studies | 4 | 2022 | 792 | 0.200 |
Why?
|
| Mouthwashes | 1 | 2003 | 6 | 0.200 |
Why?
|
| Pyrazines | 3 | 2011 | 97 | 0.200 |
Why?
|
| Neoplastic Stem Cells | 1 | 2025 | 189 | 0.200 |
Why?
|
| Tretinoin | 2 | 2021 | 129 | 0.200 |
Why?
|
| Positron-Emission Tomography | 2 | 2018 | 353 | 0.200 |
Why?
|
| Viral Vaccines | 1 | 2003 | 38 | 0.200 |
Why?
|
| Global Health | 2 | 2024 | 213 | 0.200 |
Why?
|
| Gene Expression | 5 | 2017 | 1313 | 0.200 |
Why?
|
| Cancer Care Facilities | 1 | 2003 | 36 | 0.200 |
Why?
|
| Immunoblotting | 5 | 2017 | 273 | 0.190 |
Why?
|
| United States | 12 | 2022 | 7976 | 0.190 |
Why?
|
| Phosphorylation | 7 | 2017 | 1140 | 0.190 |
Why?
|
| Travel | 1 | 2003 | 76 | 0.190 |
Why?
|
| Tongue Neoplasms | 3 | 2018 | 51 | 0.190 |
Why?
|
| Quinolones | 1 | 2003 | 57 | 0.190 |
Why?
|
| Iodine Radioisotopes | 1 | 2023 | 144 | 0.190 |
Why?
|
| Animals | 18 | 2025 | 28471 | 0.180 |
Why?
|
| Attitude to Health | 1 | 2004 | 217 | 0.180 |
Why?
|
| Precancerous Conditions | 1 | 2003 | 207 | 0.180 |
Why?
|
| Chicago | 4 | 2014 | 1488 | 0.180 |
Why?
|
| Drug Eruptions | 2 | 2017 | 34 | 0.180 |
Why?
|
| Brain Neoplasms | 3 | 2012 | 834 | 0.180 |
Why?
|
| Diffusion of Innovation | 1 | 2022 | 80 | 0.180 |
Why?
|
| Albumins | 1 | 2022 | 127 | 0.180 |
Why?
|
| Melanoma | 2 | 2005 | 511 | 0.180 |
Why?
|
| Cranial Irradiation | 3 | 2018 | 42 | 0.180 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2020 | 218 | 0.170 |
Why?
|
| Polymorphism, Genetic | 4 | 2011 | 828 | 0.170 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 51 | 0.170 |
Why?
|
| Thrombocytopenia | 2 | 2017 | 194 | 0.170 |
Why?
|
| Focal Adhesions | 2 | 2013 | 66 | 0.170 |
Why?
|
| Erythroid Precursor Cells | 1 | 2021 | 33 | 0.170 |
Why?
|
| Research Report | 1 | 2021 | 43 | 0.160 |
Why?
|
| Consolidation Chemotherapy | 2 | 2018 | 23 | 0.160 |
Why?
|
| RNA, Small Interfering | 8 | 2017 | 562 | 0.160 |
Why?
|
| Adolescent | 7 | 2022 | 9948 | 0.160 |
Why?
|
| Paxillin | 2 | 2013 | 59 | 0.160 |
Why?
|
| Sex Factors | 4 | 2019 | 1135 | 0.160 |
Why?
|
| Genomics | 3 | 2016 | 870 | 0.160 |
Why?
|
| Endpoint Determination | 2 | 2023 | 62 | 0.160 |
Why?
|
| Placebos | 5 | 2015 | 207 | 0.160 |
Why?
|
| Pyrrolidinones | 1 | 2020 | 15 | 0.160 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 430 | 0.160 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 1003 | 0.160 |
Why?
|
| Infant | 2 | 2023 | 3259 | 0.160 |
Why?
|
| Research Design | 4 | 2015 | 645 | 0.150 |
Why?
|
| Topoisomerase I Inhibitors | 5 | 2013 | 35 | 0.150 |
Why?
|
| Gene Rearrangement | 2 | 2017 | 172 | 0.150 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 1759 | 0.150 |
Why?
|
| Recurrence | 1 | 2023 | 1235 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 515 | 0.150 |
Why?
|
| Morpholines | 1 | 2019 | 64 | 0.150 |
Why?
|
| Quinolines | 1 | 2020 | 97 | 0.150 |
Why?
|
| Cell Proliferation | 9 | 2025 | 1768 | 0.150 |
Why?
|
| Mucositis | 2 | 2017 | 18 | 0.150 |
Why?
|
| Aminopyridines | 1 | 2019 | 53 | 0.150 |
Why?
|
| Survival | 3 | 2003 | 22 | 0.140 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 155 | 0.140 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 4 | 2011 | 158 | 0.140 |
Why?
|
| Radiation Injuries | 2 | 2018 | 157 | 0.140 |
Why?
|
| Hepatocyte Growth Factor | 3 | 2014 | 86 | 0.140 |
Why?
|
| Pharynx | 1 | 2018 | 43 | 0.140 |
Why?
|
| Epothilones | 2 | 2009 | 13 | 0.140 |
Why?
|
| Erythropoietin | 3 | 2013 | 90 | 0.140 |
Why?
|
| Gene Dosage | 7 | 2013 | 213 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2009 | 79 | 0.140 |
Why?
|
| Phenylurea Compounds | 4 | 2013 | 112 | 0.140 |
Why?
|
| Depsipeptides | 2 | 2010 | 30 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 527 | 0.140 |
Why?
|
| Dental Alloys | 1 | 2018 | 5 | 0.140 |
Why?
|
| Orthodontic Appliances | 1 | 2018 | 7 | 0.140 |
Why?
|
| Everolimus | 2 | 2022 | 35 | 0.140 |
Why?
|
| Radiation Pneumonitis | 1 | 2018 | 23 | 0.130 |
Why?
|
| Hemoptysis | 1 | 2018 | 25 | 0.130 |
Why?
|
| DNA Topoisomerases, Type I | 3 | 2013 | 23 | 0.130 |
Why?
|
| Ipilimumab | 3 | 2023 | 65 | 0.130 |
Why?
|
| Gene Expression Profiling | 4 | 2021 | 1551 | 0.130 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 31 | 0.130 |
Why?
|
| Skin Neoplasms | 2 | 2005 | 627 | 0.130 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2018 | 216 | 0.130 |
Why?
|
| Vision Disorders | 1 | 2018 | 74 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2013 | 2640 | 0.130 |
Why?
|
| Macrophages | 1 | 2021 | 631 | 0.130 |
Why?
|
| Transforming Growth Factor alpha | 2 | 2009 | 49 | 0.130 |
Why?
|
| Odds Ratio | 4 | 2008 | 723 | 0.130 |
Why?
|
| Mice, Nude | 4 | 2012 | 829 | 0.130 |
Why?
|
| Retreatment | 3 | 2012 | 107 | 0.130 |
Why?
|
| Pyrazoles | 3 | 2011 | 159 | 0.130 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2007 | 379 | 0.130 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 193 | 0.130 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 81 | 0.130 |
Why?
|
| Life Style | 1 | 2018 | 189 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2012 | 366 | 0.120 |
Why?
|
| Statistics, Nonparametric | 3 | 2009 | 303 | 0.120 |
Why?
|
| Recombinant Proteins | 5 | 2010 | 988 | 0.120 |
Why?
|
| Lymphatic Metastasis | 4 | 2014 | 519 | 0.120 |
Why?
|
| Paired Box Transcription Factors | 2 | 2014 | 50 | 0.120 |
Why?
|
| Celecoxib | 4 | 2017 | 34 | 0.120 |
Why?
|
| Probability | 3 | 2008 | 354 | 0.120 |
Why?
|
| Kidney Neoplasms | 3 | 2007 | 551 | 0.120 |
Why?
|
| Cell Movement | 6 | 2017 | 810 | 0.120 |
Why?
|
| SEER Program | 1 | 2016 | 239 | 0.110 |
Why?
|
| Fractals | 1 | 2015 | 41 | 0.110 |
Why?
|
| Health Status | 2 | 2009 | 382 | 0.110 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2011 | 65 | 0.110 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2015 | 41 | 0.110 |
Why?
|
| Injections, Intravenous | 2 | 2006 | 212 | 0.110 |
Why?
|
| Bryostatins | 2 | 2006 | 14 | 0.110 |
Why?
|
| Bortezomib | 3 | 2011 | 83 | 0.110 |
Why?
|
| Incidence | 5 | 2018 | 1741 | 0.110 |
Why?
|
| Radiation, Ionizing | 2 | 2012 | 123 | 0.110 |
Why?
|
| Preoperative Care | 3 | 2009 | 415 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 435 | 0.110 |
Why?
|
| Disease Models, Animal | 5 | 2024 | 2528 | 0.110 |
Why?
|
| Treatment Failure | 5 | 2010 | 295 | 0.100 |
Why?
|
| Cell Survival | 5 | 2017 | 1012 | 0.100 |
Why?
|
| Isotretinoin | 2 | 2006 | 20 | 0.100 |
Why?
|
| Gene Knockout Techniques | 1 | 2014 | 84 | 0.100 |
Why?
|
| Mass Screening | 2 | 2013 | 736 | 0.100 |
Why?
|
| Tumor Virus Infections | 1 | 2014 | 83 | 0.100 |
Why?
|
| Forecasting | 2 | 2021 | 292 | 0.100 |
Why?
|
| Risk Assessment | 7 | 2016 | 2528 | 0.100 |
Why?
|
| Glucuronosyltransferase | 2 | 2006 | 178 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 652 | 0.100 |
Why?
|
| Gene Amplification | 2 | 2018 | 141 | 0.100 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2017 | 35 | 0.100 |
Why?
|
| Interferon-alpha | 3 | 2010 | 190 | 0.100 |
Why?
|
| Population Groups | 1 | 2013 | 44 | 0.100 |
Why?
|
| Farnesyltranstransferase | 2 | 2003 | 7 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2005 | 210 | 0.100 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2013 | 15 | 0.100 |
Why?
|
| Erythropoiesis | 1 | 2013 | 52 | 0.100 |
Why?
|
| Gene Deletion | 1 | 2014 | 352 | 0.100 |
Why?
|
| Alcohol Drinking | 3 | 2018 | 297 | 0.100 |
Why?
|
| Clinical Protocols | 1 | 2013 | 161 | 0.100 |
Why?
|
| Killer Cells, Natural | 1 | 2015 | 296 | 0.100 |
Why?
|
| HeLa Cells | 1 | 2014 | 520 | 0.100 |
Why?
|
| Dehydration | 1 | 2013 | 22 | 0.100 |
Why?
|
| Esophagitis | 1 | 2013 | 40 | 0.090 |
Why?
|
| Mitochondrial Dynamics | 1 | 2013 | 60 | 0.090 |
Why?
|
| Proton Therapy | 1 | 2013 | 42 | 0.090 |
Why?
|
| Universities | 2 | 2010 | 162 | 0.090 |
Why?
|
| Osteoradionecrosis | 2 | 2010 | 18 | 0.090 |
Why?
|
| Radiation Tolerance | 2 | 2021 | 176 | 0.090 |
Why?
|
| DNA Mutational Analysis | 5 | 2017 | 546 | 0.090 |
Why?
|
| Keratin-19 | 1 | 2012 | 10 | 0.090 |
Why?
|
| Dexamethasone | 2 | 2004 | 314 | 0.090 |
Why?
|
| Ketones | 1 | 2012 | 15 | 0.090 |
Why?
|
| Furans | 1 | 2012 | 19 | 0.090 |
Why?
|
| Dinoprostone | 2 | 2025 | 80 | 0.090 |
Why?
|
| Multimodal Imaging | 1 | 2013 | 114 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2016 | 575 | 0.090 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2012 | 46 | 0.090 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2011 | 22 | 0.090 |
Why?
|
| RNA, Viral | 1 | 2013 | 287 | 0.090 |
Why?
|
| Surveys and Questionnaires | 3 | 2018 | 2951 | 0.090 |
Why?
|
| Evidence-Based Medicine | 2 | 2007 | 464 | 0.090 |
Why?
|
| Prostate-Specific Antigen | 2 | 2004 | 342 | 0.090 |
Why?
|
| Phthalazines | 1 | 2011 | 55 | 0.090 |
Why?
|
| Cancer Vaccines | 1 | 2013 | 167 | 0.090 |
Why?
|
| Ovarian Neoplasms | 2 | 2008 | 810 | 0.080 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2012 | 66 | 0.080 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2015 | 1283 | 0.080 |
Why?
|
| Analysis of Variance | 3 | 2011 | 889 | 0.080 |
Why?
|
| Hypertension | 1 | 2017 | 763 | 0.080 |
Why?
|
| Genes, ras | 1 | 2011 | 97 | 0.080 |
Why?
|
| Periodicals as Topic | 1 | 2013 | 168 | 0.080 |
Why?
|
| Rad51 Recombinase | 2 | 2014 | 81 | 0.080 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 72 | 0.080 |
Why?
|
| Receptor, EphA2 | 1 | 2010 | 5 | 0.080 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2011 | 135 | 0.080 |
Why?
|
| Mucins | 1 | 2010 | 44 | 0.080 |
Why?
|
| Community Networks | 2 | 2018 | 37 | 0.080 |
Why?
|
| Genetic Therapy | 1 | 2012 | 371 | 0.080 |
Why?
|
| Organ Preservation | 1 | 2011 | 137 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2010 | 111 | 0.080 |
Why?
|
| Antigens, Neoplasm | 1 | 2012 | 359 | 0.080 |
Why?
|
| Developing Countries | 1 | 2010 | 98 | 0.080 |
Why?
|
| Diarrhea | 3 | 2008 | 180 | 0.080 |
Why?
|
| Carcinosarcoma | 1 | 2010 | 30 | 0.080 |
Why?
|
| Tissue Array Analysis | 3 | 2017 | 135 | 0.080 |
Why?
|
| ras Proteins | 1 | 2010 | 135 | 0.080 |
Why?
|
| Postoperative Period | 1 | 2010 | 322 | 0.080 |
Why?
|
| Health Facilities | 1 | 2009 | 43 | 0.070 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2009 | 38 | 0.070 |
Why?
|
| Genotype | 5 | 2015 | 1879 | 0.070 |
Why?
|
| PAX5 Transcription Factor | 1 | 2009 | 33 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 3 | 2017 | 255 | 0.070 |
Why?
|
| Mesna | 1 | 2008 | 8 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2010 | 365 | 0.070 |
Why?
|
| Skin | 1 | 2012 | 583 | 0.070 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2008 | 43 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2011 | 324 | 0.070 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2008 | 25 | 0.070 |
Why?
|
| Macrolides | 2 | 2012 | 30 | 0.070 |
Why?
|
| Patient Care | 1 | 2009 | 100 | 0.070 |
Why?
|
| Enteral Nutrition | 2 | 2020 | 104 | 0.070 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 299 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2018 | 2647 | 0.070 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2010 | 262 | 0.070 |
Why?
|
| Mutation, Missense | 1 | 2010 | 300 | 0.070 |
Why?
|
| Pain | 2 | 2017 | 415 | 0.070 |
Why?
|
| Eicosanoids | 1 | 2008 | 18 | 0.070 |
Why?
|
| Models, Biological | 2 | 2015 | 1792 | 0.070 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2008 | 36 | 0.070 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2008 | 39 | 0.070 |
Why?
|
| Pneumonia, Aspiration | 1 | 2007 | 20 | 0.070 |
Why?
|
| Technology, Radiologic | 1 | 2008 | 103 | 0.070 |
Why?
|
| Protein Kinase C | 1 | 2008 | 263 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2009 | 580 | 0.070 |
Why?
|
| Epidermal Growth Factor | 1 | 2007 | 115 | 0.060 |
Why?
|
| Lung Diseases | 1 | 2009 | 283 | 0.060 |
Why?
|
| Tumor Burden | 3 | 2013 | 332 | 0.060 |
Why?
|
| Azacitidine | 1 | 2008 | 151 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2010 | 456 | 0.060 |
Why?
|
| Tongue | 1 | 2007 | 58 | 0.060 |
Why?
|
| Dasatinib | 3 | 2012 | 38 | 0.060 |
Why?
|
| Base Sequence | 4 | 2014 | 2219 | 0.060 |
Why?
|
| Biopsy | 3 | 2023 | 1196 | 0.060 |
Why?
|
| Multienzyme Complexes | 2 | 2004 | 54 | 0.060 |
Why?
|
| DNA Primers | 3 | 2014 | 530 | 0.060 |
Why?
|
| Oncogenes | 1 | 2007 | 102 | 0.060 |
Why?
|
| Triazines | 1 | 2007 | 55 | 0.060 |
Why?
|
| Cysteine Endopeptidases | 2 | 2004 | 89 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2004 | 109 | 0.060 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2007 | 156 | 0.060 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2006 | 12 | 0.060 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2006 | 23 | 0.060 |
Why?
|
| Surgical Flaps | 1 | 2008 | 252 | 0.060 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2006 | 21 | 0.060 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2006 | 35 | 0.060 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 123 | 0.060 |
Why?
|
| Physician's Role | 1 | 2007 | 176 | 0.060 |
Why?
|
| Phospholipids | 1 | 2006 | 108 | 0.060 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2025 | 30 | 0.060 |
Why?
|
| Activin Receptors, Type I | 1 | 2005 | 13 | 0.060 |
Why?
|
| Observation | 2 | 2020 | 37 | 0.060 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2019 | 194 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2007 | 308 | 0.060 |
Why?
|
| Illinois | 2 | 2007 | 517 | 0.060 |
Why?
|
| Anticarcinogenic Agents | 1 | 2006 | 71 | 0.060 |
Why?
|
| Societies, Medical | 2 | 2007 | 647 | 0.060 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2005 | 51 | 0.060 |
Why?
|
| Leiomyosarcoma | 1 | 2006 | 48 | 0.060 |
Why?
|
| Uterine Neoplasms | 1 | 2010 | 287 | 0.060 |
Why?
|
| Algorithms | 3 | 2013 | 1974 | 0.060 |
Why?
|
| Interleukin-2 | 1 | 2006 | 245 | 0.060 |
Why?
|
| Nausea | 1 | 2005 | 94 | 0.060 |
Why?
|
| Carbon Monoxide | 1 | 2005 | 98 | 0.060 |
Why?
|
| Liquid Biopsy | 1 | 2025 | 49 | 0.060 |
Why?
|
| Vomiting | 1 | 2005 | 109 | 0.060 |
Why?
|
| Cholangiocarcinoma | 1 | 2005 | 83 | 0.050 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2005 | 18 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2005 | 238 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2005 | 80 | 0.050 |
Why?
|
| Phagocytosis | 1 | 2025 | 115 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2025 | 119 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2006 | 294 | 0.050 |
Why?
|
| Viral Load | 1 | 2025 | 160 | 0.050 |
Why?
|
| Drugs, Essential | 1 | 2024 | 1 | 0.050 |
Why?
|
| Amino Acid Sequence | 3 | 2015 | 2003 | 0.050 |
Why?
|
| Pleura | 1 | 2024 | 31 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2006 | 1975 | 0.050 |
Why?
|
| Pharmacogenomic Testing | 1 | 2025 | 116 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2018 | 193 | 0.050 |
Why?
|
| Chemokine CXCL10 | 1 | 2024 | 24 | 0.050 |
Why?
|
| Speech Intelligibility | 1 | 2004 | 10 | 0.050 |
Why?
|
| Radiometry | 1 | 2004 | 64 | 0.050 |
Why?
|
| Stakeholder Participation | 1 | 2024 | 25 | 0.050 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2004 | 66 | 0.050 |
Why?
|
| Leukemia | 1 | 2006 | 303 | 0.050 |
Why?
|
| Voice | 1 | 2004 | 18 | 0.050 |
Why?
|
| Logistic Models | 3 | 2018 | 1270 | 0.050 |
Why?
|
| Pyrrolidines | 1 | 2004 | 61 | 0.050 |
Why?
|
| Taste | 1 | 2004 | 29 | 0.050 |
Why?
|
| Loss of Heterozygosity | 2 | 2017 | 84 | 0.050 |
Why?
|
| Contrast Media | 2 | 2009 | 1006 | 0.050 |
Why?
|
| Ligands | 1 | 2025 | 484 | 0.050 |
Why?
|
| Administration, Topical | 1 | 2003 | 80 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2004 | 71 | 0.050 |
Why?
|
| Fibroblast Growth Factors | 1 | 2004 | 87 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 226 | 0.050 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2005 | 156 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2010 | 697 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2006 | 314 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2003 | 67 | 0.050 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2003 | 30 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2003 | 305 | 0.050 |
Why?
|
| DNA Methylation | 1 | 2008 | 713 | 0.050 |
Why?
|
| Mastication | 1 | 2004 | 79 | 0.050 |
Why?
|
| Lactones | 1 | 2003 | 28 | 0.050 |
Why?
|
| Hospitals, University | 1 | 2003 | 192 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2005 | 458 | 0.050 |
Why?
|
| Patient Participation | 1 | 2025 | 244 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 759 | 0.050 |
Why?
|
| Mouth Mucosa | 1 | 2003 | 71 | 0.050 |
Why?
|
| Bias | 1 | 2003 | 138 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2004 | 155 | 0.050 |
Why?
|
| Premedication | 1 | 2003 | 57 | 0.050 |
Why?
|
| Cause of Death | 1 | 2004 | 277 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2003 | 340 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 217 | 0.050 |
Why?
|
| RNA Interference | 2 | 2017 | 381 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 2 | 2013 | 89 | 0.050 |
Why?
|
| Uncertainty | 1 | 2022 | 79 | 0.050 |
Why?
|
| Immune Tolerance | 1 | 2025 | 384 | 0.050 |
Why?
|
| Education, Medical, Continuing | 1 | 2003 | 99 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2005 | 315 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2003 | 278 | 0.040 |
Why?
|
| Receptors, CCR2 | 1 | 2021 | 34 | 0.040 |
Why?
|
| Apoptosis | 3 | 2014 | 1731 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2019 | 962 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2005 | 438 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2002 | 189 | 0.040 |
Why?
|
| Smokers | 1 | 2021 | 61 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 2 | 2015 | 731 | 0.040 |
Why?
|
| DNA Damage | 2 | 2014 | 397 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2003 | 367 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2003 | 400 | 0.040 |
Why?
|
| Comorbidity | 1 | 2004 | 1027 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2011 | 150 | 0.040 |
Why?
|
| Registries | 1 | 2006 | 1081 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 64 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2006 | 1301 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 192 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 706 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2021 | 470 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2022 | 705 | 0.040 |
Why?
|
| Health Resources | 1 | 2019 | 78 | 0.040 |
Why?
|
| Sulindac | 2 | 2009 | 8 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2025 | 3527 | 0.030 |
Why?
|
| Models, Molecular | 2 | 2015 | 1371 | 0.030 |
Why?
|
| Oral Health | 1 | 2018 | 12 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2021 | 507 | 0.030 |
Why?
|
| Transfection | 2 | 2010 | 881 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 500 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 214 | 0.030 |
Why?
|
| Age of Onset | 1 | 2018 | 354 | 0.030 |
Why?
|
| Anorexia | 1 | 2017 | 26 | 0.030 |
Why?
|
| Social Participation | 1 | 2017 | 17 | 0.030 |
Why?
|
| Sensation Disorders | 1 | 2017 | 31 | 0.030 |
Why?
|
| Metals | 1 | 2018 | 102 | 0.030 |
Why?
|
| Cooperative Behavior | 2 | 2009 | 199 | 0.030 |
Why?
|
| Weight Loss | 1 | 2019 | 241 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 685 | 0.030 |
Why?
|
| Proteolysis | 1 | 2017 | 126 | 0.030 |
Why?
|
| Dyspnea | 1 | 2017 | 88 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2009 | 893 | 0.030 |
Why?
|
| ROC Curve | 1 | 2019 | 789 | 0.030 |
Why?
|
| Decision Making | 1 | 2002 | 683 | 0.030 |
Why?
|
| Cell Line | 2 | 2011 | 2478 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2021 | 2164 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 309 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2017 | 179 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 790 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 529 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2015 | 80 | 0.030 |
Why?
|
| Thalidomide | 1 | 2015 | 57 | 0.030 |
Why?
|
| Receptors, IgG | 1 | 2015 | 69 | 0.030 |
Why?
|
| Safety | 2 | 2008 | 138 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 2005 | 3221 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2008 | 216 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2015 | 351 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 324 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2014 | 54 | 0.030 |
Why?
|
| PAX8 Transcription Factor | 1 | 2014 | 26 | 0.030 |
Why?
|
| Erythrocyte Count | 1 | 2013 | 21 | 0.020 |
Why?
|
| Genes, BRCA2 | 1 | 2014 | 162 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 196 | 0.020 |
Why?
|
| Genes, BRCA1 | 1 | 2014 | 191 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 474 | 0.020 |
Why?
|
| Autopsy | 1 | 2013 | 130 | 0.020 |
Why?
|
| Gastrostomy | 1 | 2013 | 66 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2013 | 315 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 268 | 0.020 |
Why?
|
| Alleles | 2 | 2006 | 1151 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2013 | 674 | 0.020 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2012 | 18 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 3562 | 0.020 |
Why?
|
| Ethers, Cyclic | 1 | 2012 | 8 | 0.020 |
Why?
|
| Bridged-Ring Compounds | 1 | 2012 | 16 | 0.020 |
Why?
|
| Thrombospondin 1 | 1 | 2011 | 22 | 0.020 |
Why?
|
| Barrett Esophagus | 1 | 2012 | 94 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 291 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 390 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2011 | 57 | 0.020 |
Why?
|
| Caenorhabditis elegans | 1 | 2014 | 249 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 301 | 0.020 |
Why?
|
| Computational Biology | 1 | 2015 | 591 | 0.020 |
Why?
|
| Drug Dosage Calculations | 1 | 2011 | 15 | 0.020 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2011 | 40 | 0.020 |
Why?
|
| California | 1 | 2011 | 162 | 0.020 |
Why?
|
| Lymphopenia | 1 | 2011 | 31 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 324 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2011 | 70 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 2896 | 0.020 |
Why?
|
| Organs at Risk | 1 | 2011 | 56 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 706 | 0.020 |
Why?
|
| Thorax | 1 | 2011 | 77 | 0.020 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2011 | 72 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2010 | 86 | 0.020 |
Why?
|
| Leucovorin | 1 | 2010 | 205 | 0.020 |
Why?
|
| Endonucleases | 1 | 2010 | 22 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2010 | 73 | 0.020 |
Why?
|
| Peptides | 1 | 2013 | 664 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 124 | 0.020 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2010 | 44 | 0.020 |
Why?
|
| Lymphoma, Follicular | 1 | 2010 | 73 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2010 | 77 | 0.020 |
Why?
|
| Hospitals, Veterans | 1 | 2009 | 24 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2010 | 106 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2010 | 86 | 0.020 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2009 | 3 | 0.020 |
Why?
|
| Wound Healing | 1 | 2012 | 378 | 0.020 |
Why?
|
| Semaphorins | 1 | 2009 | 17 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2009 | 53 | 0.020 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2010 | 149 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 273 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2013 | 900 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 373 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2010 | 183 | 0.020 |
Why?
|
| Darbepoetin alfa | 1 | 2008 | 5 | 0.020 |
Why?
|
| Phorbol Esters | 1 | 2008 | 19 | 0.020 |
Why?
|
| Protein Kinase C beta | 1 | 2008 | 13 | 0.020 |
Why?
|
| Demography | 1 | 2009 | 192 | 0.020 |
Why?
|
| Hematinics | 1 | 2008 | 12 | 0.020 |
Why?
|
| Pneumonia | 1 | 2010 | 194 | 0.020 |
Why?
|
| Filgrastim | 1 | 2008 | 56 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2008 | 61 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2010 | 415 | 0.020 |
Why?
|
| Community Health Services | 1 | 2009 | 79 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2010 | 518 | 0.020 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2009 | 44 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 780 | 0.020 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2010 | 187 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2008 | 41 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2009 | 235 | 0.020 |
Why?
|
| Genes, erbB-1 | 1 | 2008 | 15 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 196 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 718 | 0.020 |
Why?
|
| Exons | 1 | 2009 | 450 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2008 | 77 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 281 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2008 | 143 | 0.020 |
Why?
|
| Topotecan | 1 | 2007 | 47 | 0.020 |
Why?
|
| Health Transition | 1 | 2007 | 2 | 0.020 |
Why?
|
| Tamoxifen | 1 | 2008 | 174 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2008 | 1026 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 2007 | 138 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 408 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 215 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2009 | 607 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2008 | 376 | 0.010 |
Why?
|
| Stem Cells | 1 | 2008 | 393 | 0.010 |
Why?
|
| Aging | 1 | 2011 | 757 | 0.010 |
Why?
|
| Video Recording | 1 | 2007 | 218 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2009 | 837 | 0.010 |
Why?
|
| Mandibular Diseases | 1 | 2005 | 17 | 0.010 |
Why?
|
| Urogenital Neoplasms | 1 | 2005 | 25 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2008 | 737 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2005 | 207 | 0.010 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2005 | 111 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2005 | 127 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 2004 | 42 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 547 | 0.010 |
Why?
|
| Receptors, Endothelin | 1 | 2004 | 12 | 0.010 |
Why?
|
| Antidiarrheals | 1 | 2004 | 14 | 0.010 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2005 | 102 | 0.010 |
Why?
|
| Research | 1 | 2005 | 256 | 0.010 |
Why?
|
| Genital Neoplasms, Female | 1 | 2005 | 116 | 0.010 |
Why?
|
| Bilirubin | 1 | 2004 | 135 | 0.010 |
Why?
|
| Benzamides | 1 | 2005 | 257 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2008 | 456 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 2004 | 239 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2005 | 354 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 1796 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 659 | 0.010 |
Why?
|
| Biological Availability | 1 | 2002 | 85 | 0.010 |
Why?
|
| Cytokines | 1 | 2006 | 883 | 0.010 |
Why?
|
| Hematologic Neoplasms | 1 | 2005 | 378 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 1973 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 1549 | 0.010 |
Why?
|
| Child | 1 | 2012 | 7540 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2004 | 515 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2004 | 581 | 0.010 |
Why?
|
| Liver | 1 | 2004 | 1222 | 0.010 |
Why?
|
| Phenotype | 1 | 2005 | 2602 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2004 | 863 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2004 | 1434 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 2494 | 0.010 |
Why?
|